Deleted Tweets From Scott Gottlieb, R-D.C.

RT @hbottemiller: New: FDA is changing its policy to allow inspectors working w/o pay (think high-risk food safety inspection in Chin… https://t.co/n7Fzw0VZC6

Our report on 2018 drug approvals. It was a record year for novel drug approvals with an all time high of 59 NMEs approved by our drug center. https://t.co/DQ0esqS49j

RT @matthewherper: Exclusive: FDA plans to create a new office to leverage cutting-edge science https://t.co/5ySY3mMEbw featuring futuristic comments by @SGottliebFDA.

We’re releasing our Regulatory Framework that describes how we intend to use our De Novo pathway for novel technologies to implement the next phase of the Pre-Cert pilot. https://t.co/oTIIfxXt55

We’re also issuing our Pre-Cert Test Plan for 2019 to assess how using a streamlined De Novo pathway compares to the traditional pathway, ensuring it can maintain our standards for assuring safe and effective devices, while still modernizing our review. https://t.co/AQ31bB5U1D

RT @GideonGil: .@SGottliebFDA envisions drug company data being uploaded into the cloud, "and instead of looking at the charts and tables companies create themselves, the FDA will use its own standardized methods on the raw data" https://t.co/xsAhu7cceR via @statnews

THREAD: Today we’re announcing the next phase of our Pre-Cert Pilot Program to test new approaches for the review of digital health devices to help support the development of new technologies that meet our safety and effectiveness standard. https://t.co/IItNdnSQS9 https://t.co/3rrz8wjTL5

We’re also updating our Pre-Cert Working Model to incorporate the Framework and Test Plan so we can understand how well Pre-Cert will work now, and also help establish the components we envision for the future of Pre-Cert. https://t.co/Kat08m9RZp

Through the dedicated work of CDER professional staff, #FDA was able to set and break records for drug approvals in 2018. #FDAVoices posted today highlights the goals and efficiencies through which we were able to bring new drug therapies to approval. https://t.co/AhBDbbp23R 3/4

THREAD: 2018 was a year of many drug-related firsts for #FDA and record novel drug approvals. Many will have a significant impact on improving health. We've outlined details on the new products in our "New Drug Therapy Approvals" report issued today https://t.co/AhBDbbp23R 1/4 https://t.co/9bsUesJvnV

The #FDA's center for drugs "New Drug Therapy Approvals" report highlights several 2018 key accomplishments including drug approvals critical to helping people living with rare diseases. https://t.co/AhBDbbp23R 2/4

I’ll be providing new updates later today on how our Biosimilars program (BSUFA) is impacted by the lapse in funding. #shutdown

RT @FDAcdrhIndustry: @SGottliebFDA sharing new information about the #DigitalHealth Software Precertification Pilot #FDAPrecertPilot, in… https://t.co/uFakGxDzhA

RT @SGottliebFDA: My note to our inspectorate today. We’re taking new steps to bill travel costs to a central #FDA account so our fie… https://t.co/7nc4w1tqbV

In 2018, CDER met its PDUFA goal for 100% of the novel drugs approved – 95% of which on the first cycle – reflecting our efficiency in getting new therapies to patients quickly. Read our #FDAVoices New Drug Therapy Approvals Report to learn more. https://t.co/AhBDbbp23R 4/4

RT @FDAMedia: Statement from FDA Commissioner @SGottliebFDA, on the agency’s new actions under the Pre-Cert Pilot Program to promote a more efficient framework for the review of safe and effective digital health innovations https://t.co/o5OsgdGsI0

We have lots of questions from media about hiring during this lapse in appropriations. We've had to hold off on unfunded recruitment efforts. All our staff is critical. We look forward to bringing additional new scientific and professional staff into FDA once funding is restored

Despite the #shutdown, today I was pleased to welcome 32 new user-fee funded employees to FDA. We're delighted to have them, and thankful that carryover balances allow us to finalize their start. Important to note, it represents only 48% of new staff we planned to on-board today. https://t.co/o2Yd7NiVfR

#FDA is broadening the reach of its “The Real Cost” Smokeless Tobacco Prevention campaign - which originally aimed to educate nearly 600K male teens in 35 rural U.S. markets - to place new ads in 20 states to ultimately reach nearly 3 million more youth. https://t.co/ptuNMOqPWK

RT @FrankYiannasFDA: In a first of its kind, ‘Food Safety’ to take center stage in opening keynote at the Consumer Electronic Show @CES… https://t.co/CYG3ZMje8u

RT @hbottemiller: New: FDA is changing its policy to allow inspectors working w/o pay (think high-risk food safety inspection in Chin… https://t.co/n7Fzw0VZC6

Our report on 2018 drug approvals. It was a record year for novel drug approvals with an all time high of 59 NMEs approved by our drug center. https://t.co/DQ0esqS49j

RT @matthewherper: Exclusive: FDA plans to create a new office to leverage cutting-edge science https://t.co/5ySY3mMEbw featuring futuristic comments by @SGottliebFDA.

We’re releasing our Regulatory Framework that describes how we intend to use our De Novo pathway for novel technologies to implement the next phase of the Pre-Cert pilot. https://t.co/oTIIfxXt55

We’re also issuing our Pre-Cert Test Plan for 2019 to assess how using a streamlined De Novo pathway compares to the traditional pathway, ensuring it can maintain our standards for assuring safe and effective devices, while still modernizing our review. https://t.co/AQ31bB5U1D

RT @GideonGil: .@SGottliebFDA envisions drug company data being uploaded into the cloud, "and instead of looking at the charts and tables companies create themselves, the FDA will use its own standardized methods on the raw data" https://t.co/xsAhu7cceR via @statnews

THREAD: Today we’re announcing the next phase of our Pre-Cert Pilot Program to test new approaches for the review of digital health devices to help support the development of new technologies that meet our safety and effectiveness standard. https://t.co/IItNdnSQS9 https://t.co/3rrz8wjTL5

We’re also updating our Pre-Cert Working Model to incorporate the Framework and Test Plan so we can understand how well Pre-Cert will work now, and also help establish the components we envision for the future of Pre-Cert. https://t.co/Kat08m9RZp

Through the dedicated work of CDER professional staff, #FDA was able to set and break records for drug approvals in 2018. #FDAVoices posted today highlights the goals and efficiencies through which we were able to bring new drug therapies to approval. https://t.co/AhBDbbp23R 3/4

THREAD: 2018 was a year of many drug-related firsts for #FDA and record novel drug approvals. Many will have a significant impact on improving health. We've outlined details on the new products in our "New Drug Therapy Approvals" report issued today https://t.co/AhBDbbp23R 1/4 https://t.co/9bsUesJvnV

The #FDA's center for drugs "New Drug Therapy Approvals" report highlights several 2018 key accomplishments including drug approvals critical to helping people living with rare diseases. https://t.co/AhBDbbp23R 2/4

I’ll be providing new updates later today on how our Biosimilars program (BSUFA) is impacted by the lapse in funding. #shutdown

RT @FDAcdrhIndustry: @SGottliebFDA sharing new information about the #DigitalHealth Software Precertification Pilot #FDAPrecertPilot, in… https://t.co/uFakGxDzhA

RT @SGottliebFDA: My note to our inspectorate today. We’re taking new steps to bill travel costs to a central #FDA account so our fie… https://t.co/7nc4w1tqbV

In 2018, CDER met its PDUFA goal for 100% of the novel drugs approved – 95% of which on the first cycle – reflecting our efficiency in getting new therapies to patients quickly. Read our #FDAVoices New Drug Therapy Approvals Report to learn more. https://t.co/AhBDbbp23R 4/4

RT @FDAMedia: Statement from FDA Commissioner @SGottliebFDA, on the agency’s new actions under the Pre-Cert Pilot Program to promote a more efficient framework for the review of safe and effective digital health innovations https://t.co/o5OsgdGsI0

We have lots of questions from media about hiring during this lapse in appropriations. We've had to hold off on unfunded recruitment efforts. All our staff is critical. We look forward to bringing additional new scientific and professional staff into FDA once funding is restored

Despite the #shutdown, today I was pleased to welcome 32 new user-fee funded employees to FDA. We're delighted to have them, and thankful that carryover balances allow us to finalize their start. Important to note, it represents only 48% of new staff we planned to on-board today. https://t.co/o2Yd7NiVfR

#FDA is broadening the reach of its “The Real Cost” Smokeless Tobacco Prevention campaign - which originally aimed to educate nearly 600K male teens in 35 rural U.S. markets - to place new ads in 20 states to ultimately reach nearly 3 million more youth. https://t.co/ptuNMOqPWK

RT @FrankYiannasFDA: In a first of its kind, ‘Food Safety’ to take center stage in opening keynote at the Consumer Electronic Show @CES… https://t.co/CYG3ZMje8u